There is no ketamine dosing room in Tampa at Ascend, and we are not going to pretend otherwise. Every dose is given at one address: Ascend Mind and Body, 27724 Cashford Circle, Suite 102, Wesley Chapel, FL 33544. What this page is for is the part Tampa patients actually have to solve, which is getting there, getting home, and knowing what the medication is before you agree to it. The psychiatric evaluation that decides whether ketamine is appropriate can be done by Florida telehealth from anywhere in Hillsborough County. Call (813) 670-3005 or book a consultation.
Getting to Cashford Circle from your part of Tampa
Tampa is not one drive, it is about six of them, and the honest answer changes a lot depending on which side of the city you start from. New Tampa is close enough that this is effectively a neighborhood clinic. South Tampa is not. Plan from the number that matches your address rather than the average.
| Starting from | Usual route | Approx. time |
|---|---|---|
| New Tampa, Tampa Palms, Hunter's Green | Bruce B. Downs Blvd north, or I-75 north one or two exits | 15 to 20 minutes |
| Temple Terrace, USF area | I-75 north to SR 56 east | 20 to 30 minutes |
| Carrollwood, Northdale | Dale Mabry Hwy north to SR 54 east, or the Veterans Expressway | 25 to 35 minutes |
| Seminole Heights, downtown, Channel District | I-275 north to I-75 north, then SR 56 | 30 to 40 minutes |
| South Tampa, Hyde Park, Westshore | Veterans Expressway north to SR 54 east | 40 to 50 minutes |
The suite is on the ground floor off SR 54 near Meadow Pointe Boulevard, roughly two minutes from the Shops at Wiregrass. Parking is free and on site, so there is no garage, no ticket, and no lift. Clinic hours are Monday through Friday, 8:00 AM to 5:00 PM. If you are coming from the southern half of the city, the honest advice is to avoid booking anything that lands you on I-275 northbound between 4:00 and 6:30 PM, because that single choice adds more time than the route itself.
The ride home is the part people underestimate
You will not be cleared to drive after a session, and this is not a formality we waive if you feel fine. A team member confirms your ride at check-in before anything is administered. For Tampa patients that produces three workable patterns, and it is worth picking one before you book rather than after.
- A partner or friend drives both ways. The simplest option, and the one most patients settle on. Budget roughly three hours of their day per session once travel is included.
- Rideshare back down I-75. Practical from most of Tampa. Book it at discharge rather than in advance, because recovery observation does not run to a fixed clock.
- Clustered scheduling. Asking for consecutive-day appointments reduces the number of separate trips someone has to make for you across the induction window.
Plan the rest of the day as a write-off. Most patients feel tired or foggy for several hours afterward, and trying to return to work or childcare straight from a session tends to go badly.
Where Ascend sits among the Tampa options
Searching for ketamine in Tampa returns three genuinely different things, and they are easy to confuse because the marketing language overlaps. Free-standing infusion centers deliver racemic ketamine through a drip line, often on a fixed protocol and with staff who may change between visits. National telehealth services mail lozenges to your home for you to take with nobody in the room. Ascend is neither. It is a psychiatric practice that provides ketamine therapy, using a subcutaneous injection of a compounded ketamine preparation that is not FDA-approved, given and monitored in a private treatment room, with the same prescriber directing every session.
Anna Stouffer, MS, PMHNP-BC, FNP-BC runs the evaluation, sets the dosing plan, and reviews your response after every visit. She is dual board-certified in psychiatric-mental health and family practice, which means the cardiovascular and medication review that decides candidacy happens in the same appointment rather than as a separate clearance step. If ketamine turns out not to be a sensible option for you, the alternative conversation happens inside the same practice instead of starting over with a stranger.
Four questions are worth asking any program you are weighing, including this one: who performs the evaluation and are they a licensed prescriber, is a clinician present for the whole dosing window, what is monitored during and after, and what happens if the induction series produces nothing. Pricing is discussed when we call you back rather than published, because the answer depends on what your evaluation concludes you actually need.
What the medication is, and its regulatory status
Ketamine is not FDA-approved to treat depression, PTSD, anxiety, OCD, or chronic pain. The preparation used at Ascend is compounded, meaning a pharmacy puts it together rather than a manufacturer producing a finished reviewed product, and a compounded medication is not FDA-approved for any use, this one included. The agency has not assessed what we give you for safety, for effectiveness, or for manufacturing quality. You will hear this again at your evaluation, in plain language, with time to ask about it before you decide anything.
Two practical consequences follow from that status. First, because the compounded preparation is not FDA-approved, we never mail it and never hand you a supply to take on your own; every dose is prepared for in-clinic use and given here. The FDA has issued public warnings about exactly the practice we decline, which is compounded ketamine shipped to people to self-administer without monitoring. Second, most of the published research was run on infusion administration rather than the subcutaneous route used here, so the evidence transfers by inference rather than directly. We would rather say that than imply the trials studied precisely what you will receive.
Ketamine is a Schedule III controlled substance with recognized potential for misuse and dependence, which is why dosing frequency is set by the clinic and reassessed at every follow-up rather than left open-ended. Before a first dose you complete a full psychiatric evaluation with a licensed prescriber and sign an informed consent that names the compounded, not FDA-approved status of the medication, its risks, and the alternatives. Nasal-spray and at-home programs are not offered here.
Who gets evaluated, and who gets screened out
Treatment-resistant depression, generally an inadequate response to two or more antidepressants taken at therapeutic doses for an adequate length of time, is the primary and most studied indication. PTSD is evaluated after trauma-focused therapy and first-line medication, and severe anxiety that has resisted standard treatment is assessed on a smaller evidence base. OCD, bipolar depression, and select chronic pain conditions are considered individually. None of these are assessed as certain to respond.
Screening exists to find the patients for whom this is a poor idea before anyone drives north for a first dose. Severe or uncontrolled cardiovascular disease, uncontrolled hypertension, active psychosis or a documented primary psychotic disorder, active or untreated substance use disorders, and pregnancy all come up during the evaluation and can make ketamine inappropriate. Bring a complete current medication list including supplements; benzodiazepines, stimulants, several blood pressure medications, and MAOIs are all reviewed, and lithium or another mood stabiliser calls for closer coordination rather than exclusion.
Side effects during a session are usually mild and settle before discharge: short-lived dizziness or nausea, brief rises in heart rate and blood pressure, perceptual changes during the active window, and sometimes a headache or fatigue afterward. Dissociation is expected rather than a complication, which is why nobody is left alone. If you are in immediate danger, call or text 988; ketamine therapy is scheduled care, not an emergency service.
What the evidence supports, stated carefully
The foundational randomized controlled trial (Zarate CA Jr, et al., Archives of General Psychiatry, 2006) established a rapid antidepressant signal in treatment-resistant patients, working through NMDA receptor antagonism and glutamate signalling rather than the serotonin pathway most antidepressants target. A consensus statement developed with the American Psychiatric Association (Sanacora G, et al., JAMA Psychiatry, 2017) set out how that should translate into clinical practice and where the limits sit. A placebo-controlled pilot trial testing routes of administration (Loo CK, et al., Acta Psychiatrica Scandinavica, 2016) reported response rates for the subcutaneous route broadly comparable to what the infusion literature had described, with a simpler delivery process and a shorter monitoring window than a maintained line.
All of that describes what happened to groups of research participants under research conditions. It is not a forecast for you. Ketamine remains not FDA-approved for any of the conditions named on this page, and that does not change because a trial reported a positive result. Some patients respond, some respond only partially, and a real minority notice nothing meaningful across a full induction series. That outcome is discussed directly at follow-up rather than answered with more sessions.
Tampa questions we get asked
Does Ascend have a Tampa dosing location?
No. Ascend has one ketamine site and it is in Wesley Chapel, at 27724 Cashford Circle, Suite 102. Tampa patients are evaluated through the practice, often by Florida telehealth, and every dose is given at that Wesley Chapel suite. We would rather tell you that here than have you discover it after booking.
I live in New Tampa. Is this closer than driving into the city?
For most New Tampa addresses, yes. Tampa Palms, Hunter's Green, and the Bruce B. Downs corridor sit 15 to 20 minutes from the suite, which is usually less than the trip to a downtown or Westshore medical district. It is one of the few situations where the closest option and the option you would choose anyway are the same.
Can I schedule around a weekday job?
Partly. The evaluation is available by Florida telehealth and can usually be fitted into a lunch break or a late-afternoon slot. Dosing sessions cannot be treated the same way. They run about two hours inside clinic hours, you cannot drive afterward, and the rest of the day is realistically gone. Most working Tampa patients cluster sessions or use partial days rather than trying to slot them around a full shift.
Why not use an at-home ketamine service instead?
That is a real choice and worth understanding rather than dismissing. The difference is supervision. At-home services send a compounded oral or sublingual preparation for you to take with no clinician present and no vital signs recorded. Ascend gives a subcutaneous injection in a private room with monitoring before, during, and after, and does not mail medication. The compounded preparation is not FDA-approved either way, so the supervision is the variable you are actually choosing between.
Do you take insurance for this?
Coverage for racemic ketamine is inconsistent and most often out of network, and we do not bill insurance for the ketamine sessions themselves. The psychiatric consultation may be partially covered by in-network psychiatric benefits depending on your plan. Our insurance and payment page covers what we can and cannot verify in advance.
How fast can a Tampa patient actually start?
The limiting step is the evaluation, not the calendar. That appointment happens first, it takes about an hour, and it may conclude that ketamine is not the right next step for you. If it is appropriate, the induction series runs six sessions across roughly two to three weeks, so the practical question becomes how quickly you can arrange transport for six visits rather than how quickly we can book you.
For the full clinical walkthrough of a dosing day, including monitoring and what the medication feels like, see the Wesley Chapel ketamine page, which is where treatment actually happens. The service-wide overview lives on Ascend's ketamine therapy page.
References
- Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006;63(8):856-864.
- Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399-405.
- Loo CK, Galvez V, O'Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica. 2016;134(1):48-56.